

**No dossier** 83B18  
**ID patient** KOEG05051981  
**Type prélèv.** Plasma  
**Date échantillon** 20/06/2018  
**Sous-type** CRF02\_AG  
**Charge virale** 16370  
**Service demand.** IMMUNOLOGIE CLINIQUE

**Nucleoside Reverse Transcriptase Inhibitors (NRTI)**

Drug	Mutations list	Range	Color	Interpretation
Epivir® / Emtriva® Lamivudine / Emtricitabine (3TC_FTC)	<b>184V</b>	3	Red	R - Resistance
Ziagen® Abacavir (ABC)	<b>67N, 74I, 184V</b>	3	Red	R - Resistance
Viread® Tenofovir Alafenamide (TDF_TAF)	<b>67N, 70E, 74I</b>	3	Red	R - Resistance
Retrovir® Zidovudine (ZDV)	<b>67N</b>	1	Green	S - Susceptible

**Non-Nucleoside Reverse transcriptase Inhibitors (NNRTI)**

Drug	Mutations list	Range	Color	Interpretation
Doravirine (DOR)	<b>103N, 225H</b>	3	Red	R - Resistance
Sustiva®, Stocrin® Efavirenz (EFV)	<b>103N, 225H</b>	3	Red	R - Resistance
Intelence® Etravirine TMC125 (ETR)	<b>90I, 106I</b>	2	Yellow	I - Possible resistance
Viramune® Nevirapine (NVP) *	<b>103N</b>	3	Red	R - Resistance
Rilpivirine (RPV)	<b>103N</b>	1	Green	S - Susceptible

**Protease Inhibitors (PI)**

Drug	Mutations list	Range	Color	Interpretation
Reyataz® / Norvir® 300/100 Atazanavir / Ritonavir (ATV_RTV)	<b>16E</b>	1	Green	S - Susceptible
Prezista® / Norvir® 600/100 BID Darunavir TMC114 / Ritonavir (DRV_RTV_BID)		1	Green	S - Susceptible
Prezista® / Norvir® 800/100 QD Darunavir TMC114 / Ritonavir (DRV_RTV_QD)		1	Green	S - Susceptible
A component of Kaletra® Lopinavir (LPVr)		1	Green	S - Susceptible
Aptivus® / Norvir® 500/200 Tipranavir / Ritonavir (TPV_RTV) **	<b>36I, 69K, 89M</b>	3	Red	R - Resistance

**Integrase Strand Transfer Inhibitors (INSTI)**

Drug	Mutations list	Range	Color	Interpretation
Cabotegravir (CAB)	<b>157Q</b>	2	Yellow	I - Possible resistance
Dolutegravir BID (DTG_BID)		1	Green	S - Susceptible
Dolutegravir QD (DTG_QD)	<b>157Q</b>	2	Yellow	I - Possible resistance
Elvitegravir (EVG)	<b>157Q</b>	3	Red	R - Resistance
Isentress® Raltegravir (RAL)	<b>157Q</b>	3	Red	R - Resistance

For provirus DNA, impact of stop codons and G->A mutations on ARV resistance is unknown.

(\*) In presence of mutation 98S in RT for HIV-1 subtype C, Nevirapine (NVP) interpretation should be considered as resistant

(\*\*) Insufficient data for HIV-1 subtype non-B

ASI Drug Resistance Algorithm ANRS 2018.28/sg/b

**Signature:** Magali Bouvier-Alias

<b>No dossier</b>	83B18	<b>Date échantillon</b>	20/06/2018
<b>ID patient</b>	KOEG05051981	<b>Sous-type</b>	CRF02_AG
<b>Type prélèv.</b>	Plasma	<b>Charge virale</b>	16370
		<b>Service demand.</b>	IMMUNOLOGIE CLINIQUE

**Extra Parameters**

<b>IDNS Version</b>	v3_8_1r1(r31140)	<b>Algorithm version</b>	2018.28/sg/b
<b>Drug Resistance Algorithm</b>	ANRS		
<b>Algorithm fingerprint</b>	35341ac2f82bff446dcae49db46c7bf5		
<b>Date de création du rapport</b>	03.07.2018		

<b>Mutations PR</b>	3I, 13V, 14K, 14R, 16E, 20I, 36I, 37N, 41K, 69K, 70K, 70R, 72Q, 89M	<b>Mutations RT</b>	20R, 22K, 22R, 28A, 35T, 39A, 40D, 67N, 68N, 68S, 70E, 74I, 90I, 101K, 101Q, 103N, 106I, 106V, 123N, 123S, 135V, 162A, 173T, 174K, 174E, 177E, 178L, 184V, 188Y, 188F, 200A, 207E, 214F, 218D, 218E, 225H, 225P, 238K, 238R, 238E, 238G, 245Q, 248N, 248D, 270T, 270S, 270A, 270G, 272A, 275R, 277K, 286A, 291D, 293V, 294T, 317A, 322T, 322A, 329I, 329V, 335D, 335G
		<b>Mutations IN</b>	10E, 14R, 31I, 46Q, 72I, 101I, 112T, 112I, 112A, 112V, 123S, 125A, 127K, 134N, 135V, 136T, 157Q, 157E, 194C, 201I, 206S, 211R, 232D, 234I

**Signature:** Magali Bouvier-Alias